Angiotensin-converting enzyme 2 inhibits high-mobility   group box 1 and attenuates cardiac dysfunction post-myocardial   ischemia.
High-mobility group box 1 (HMGB1) triggers and amplifies inflammation cascade following ischemic injury, and its elevated levels are associated with adverse clinical outcomes in patients with myocardial infarction (MI). Angiotensin-converting enzyme 2 (ACE2), a key member of vasoprotective axis of the renin-angiotensin system (RAS), regulates cardiovascular functions and exerts beneficial effects in cardiovascular disease. However, the association between HMGB1 and ACE2 has not been studied. We hypothesized that overexpression of ACE2 provides cardioprotective effects against MI via inhibiting HMGB1 and inflammation. ACE2 knock-in (KI) mice and littermate wild-type (WT) controls were subjected to either sham or coronary artery ligation surgery to induce MI. Heart function was assessed 4 weeks after surgery using echocardiography and Millar catheterization. Tissues were collected for histology and analysis of the expression of HMGB1, RAS components, and inflammatory cytokines. ACE2 in the heart of the ACE2 KI mice was 58-fold higher than WT controls. ACE2-MI mice exhibited a remarkable preservation of cardiac function and reduction of infarct size in comparison to WT-MI mice. Notably, ACE2 overexpression significantly reduced the MI-induced increase in apoptosis, macrophage infiltration, and HMGB1 and proinflammatory cytokine expression (TNF-α and IL-6). Moreover, in an in vitro study, ACE2 activation prevented the hypoxia-induced cell death and upregulation of HMGB1 in adult cardiomyocytes. This protective effect is correlated with downregulation of HMGB1 and downstream proinflammatory cascades, which could be useful for the development of novel treatment for ischemic heart disease.
Yan Fei
YF
Qi
Juan
J
Zhang
Lei
L
Wang
Vinayak
V
Shenoy
Eric
E
Krause
S Paul
SP
Oh
Carl J
CJ
Pepine
Michael J
MJ
Katovich
Mohan K
MK
Raizada
D000085962:Angiotensin-Converting Enzyme 2; D000809:Angiotensins / Q000378:metabolism*; D000818:Animals; D017209:Apoptosis / Q000276:immunology; D002316:Cardiotonic Agents / Q000378:metabolism; D015536:Down-Regulation; D055879:Gene Knock-In Techniques; D024243:HMGB1 Protein / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000276:immunology; D015850:Interleukin-6 / Q000096:biosynthesis; D051379:Mice; D009203:Myocardial Infarction / Q000473:pathology*; D032383:Myocytes, Cardiac / Q000378:metabolism*; D007703:Peptidyl-Dipeptidase A / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D013318:Stroke Volume / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000809:Angiotensins; D002316:Cardiotonic Agents; D024243:HMGB1 Protein; C582808:HMGB1 protein, mouse; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; C577686:interleukin-6, mouse; D007703:Peptidyl-Dipeptidase A; C000705307:ACE2 protein, human; C000705328:Ace2 protein, mouse; D000085962:Angiotensin-Converting Enzyme 2